Page 6 - Hybrid Congress News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomLina liseniorJohn leonardKallikrein reductionasTimothyj craigEuropean academy of allergyBiomedical sciences at penn state universityIntellia therapeutics incExchange commissionCorporate communicationsExtended phaseEuropean academyClinical immunologyHybrid congressIntellia presidentChief executive officer

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Study Shows Promising Results for Immunotherapy Targeting Skin Cancer

HAMBURG, Germany, June 11, 2023 /PRNewswire/ A ground-breaking study was presented 10 June at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology

City ofUnited kingdomJames spicerJitesh chauhanSophia karagiannisHeather baxKing college londonNational allergy societiesPostdoctoral researchEuropean academy of allergyEpsilogen ltdJohn institute of dermatologyEuropean academy of allergy clinical immunologyHybrid congressEuropean academyClinical immunology

Intellia Therapeutics Announces New Positive Clinical Data

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients.

United kingdomIan karpJohn leonardAlina liTimothyj craigMatt crensonExchange commissionCorporate communicationsIntellia therapeutics incBiomedical sciences at penn state universityEuropean academy of allergyClinical programExtended phaseEuropean academyClinical immunologyHybrid congress

Data of Deucrictibant for the On-Demand Treatment of HAE

Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant.

United kingdomUnited statesWim souverijnsMarcus maurerEmel aygPeng luEuropean academy of allergy clinical immunologyCommunity engagementExchange commissionUniversity hospital frankfurtEuropean unionEuropean academyClinical immunologyHybrid congressUniversity hospitalChief community engagement

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

United statesUnited kingdomMarcus maurerPeng luWim souverijnsEmel aygExchange commissionCommunity engagementUniversity hospital frankfurtEuropean academy of allergy clinical immunologyEuropean unionEuropean academyClinical immunologyHybrid congressUniversity hospitalChief community engagement